Proteins and Peptides

19 March 2015

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

19 March 2015

CollPlant Reports Positive Interim Trial Results for Vergenix®FG Wound Healing Gel

19 March 2015

Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)

18 March 2015

Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria

17 March 2015

Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study

16 March 2015

biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score

16 March 2015

Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

13 March 2015

Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant Treatment for Hemophila A and B Patients with Inhibitors

12 March 2015

Protalex Initiates Enrollment of Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients

10 March 2015

PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen’s investigational enzyme replacement therapies, AGT-182 and AGT-181, for Phase 1 Clinical Trial

9 March 2015

Horizon Pharma plc Announces That Pre-Clinical Data Show Treatment With Interferon Gamma Improved Signs of Disease Severity of Rare Bone Disease

9 March 2015

Novo Nordisk – New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® showed improvement in blood glucose, CV risk factors and quality of life outcomes

7 March 2015

Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine Society’s Annual Meeting

6 March 2015

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

6 March 2015

AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV Applying Ropeginterferon ALFA 2B, a Novel, Long-Acting, Mono-Pegylated Interferon for Treatment of Polycythemia Vera

6 March 2015

Chiasma Announces New Data for Investigational Octreotide Capsules

5 March 2015

Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure

4 March 2015

FDA Accepts Bayer’s Biologics License Application for Investigational Treatment Option in Hemophilia A

2 March 2015

Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

2 March 2015

Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)

2 March 2015

Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

27 February 2015

Toujeo® Receives Positive Opinion from the European Regulatory Authorities

27 February 2015

Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma

26 February 2015

DS Healthcare Announces Discovery Of New Peptide

26 February 2015

Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®

23 February 2015

FDA Accepts BLA Filing For Synageva’s Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date

23 February 2015

Lilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro

20 February 2015

Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes

18 February 2015

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)

17 February 2015

Dipexium Pharmaceuticals Announces Successful Completion and Initial Results of Phase 1 Skin Sensitization Trial of Locilex®

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

PD-1 Agonists Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Report Package: Bispecific Antibodies